# Peptides Studied for Kidney Disease: The Trials | PepVault

Source: https://pepvault.app/conditions/kidney-disease

Last updated: 2026-11-19

Use: © PepVault. Read and cite with a link. Copying, bulk scraping, rewriting or republishing is not permitted (https://pepvault.app/terms#content).

[Research](https://pepvault.app/research) [By condition](https://pepvault.app/conditions) Kidney Disease

Peptides by condition · Heart, kidneys and lungs

# Peptides studied for kidney disease

Checked November 2026 against our study pages and the FDA labels [Published by PepVault](https://pepvault.app/guides/how-we-research)

Our library holds 3 study pages on kidney disease: 2 in people (all meta-analyses or randomized trials), and 1 in animals. They studied 3 compounds, with this many study pages each: Semaglutide 1, SS-31 1 and Ac-SDKP 1.

## What the research on kidney disease looks like

Kidney disease is a slow loss of the kidneys’ ability to filter the blood, most often driven by diabetes and high blood pressure. Our study pages on it are few and varied, from a large trial in people with diabetes and kidney disease to small early studies of the kidney’s blood supply and of scarring in mice.

Kidney trials follow eGFR, an estimate of how much blood the kidneys filter each minute, and count hard events such as kidney failure, dialysis or death. Smaller studies look at oxygen and blood flow in the kidney, or at scarring in tissue.

A large trial with kidney failure as its outcome is much stronger evidence than a short pilot or a mouse study. Look at who was enrolled, because kidney disease from diabetes is not the same as kidney damage from a narrowed artery.

How many of the 3 study pages on this condition reach each design, strongest at the top: meta-analyses and randomized trials in people, other studies in people, animals, cells.

<!--promo-->

PepVault for iPhone

## Track your own progress in PepVault

Doses, vials, weight and side effects in one log.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=conditions-card-flow&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## The 3 studies, by compound

Grouped by the compound each study is filed under, and within each, strongest design first. Each line gives the design, who was studied, how many and the year, before the finding.

1. ### [Semaglutide](https://pepvault.app/peptides/semaglutide)

   1 in people

   For kidney disease, 1 of our study pages is filed under Semaglutide: 1 randomized trial in people. It enrolled 3,533 people and was published in 2024, in N Engl J Med.

   FDA-approved, with a use tied to kidney disease on its label: Ozempic (injection) for blood sugar control in adults with type 2 diabetes, and lowering the risk of heart attack, stroke and kidney decline in those with heart or kidney disease; Ozempic (tablet) for blood sugar control in adults with type 2 diabetes, and lowering the risk of heart attack and stroke in those at high risk (the same label as Rybelsus). Under Rybelsus and Wegovy it is approved for other uses.

   - Randomized trial in people · 3,533 people · 2024 [Semaglutide: 24% lower risk of major kidney events in FLOW](https://pepvault.app/research/semaglutide-flow-2024)

   - [Ozempic, from its FDA label](https://pepvault.app/drugs/ozempic)
   - [Semaglutide: legal and regulatory status](https://pepvault.app/peptides/semaglutide/legal-status)
   - [Semaglutide in the library](https://pepvault.app/peptides/semaglutide)
   - [Semaglutide dose guide](https://pepvault.app/lab/dosage/semaglutide)
2. ### [SS-31](https://pepvault.app/peptides/ss-31)

   1 in people

   For kidney disease, 1 of our study pages is filed under SS-31: 1 randomized trial in people. It was published in 2017, in Circ Cardiovasc Interv, and our page does not give its size.

   FDA-approved for other uses, not for kidney disease: Forzinity (injection) for improving muscle strength in adults and children with Barth syndrome who weigh at least 30 kg (an accelerated approval; it may depend on a confirmatory trial).

   - Randomized trial in people · 2017 [SS-31: less kidney hypoxia after renal artery stenting in pilot](https://pepvault.app/research/ss-31-saad-2017)

   - [SS-31: legal and regulatory status](https://pepvault.app/peptides/ss-31/legal-status)
   - [SS-31 in the library](https://pepvault.app/peptides/ss-31)
   - [SS-31 dose guide](https://pepvault.app/lab/dosage/ss-31)
3. ### [Ac-SDKP](https://pepvault.app/peptides/tb-500-fragment)

   1 in animals

   For kidney disease, 1 of our study pages is filed under Ac-SDKP: 1 animal study (mice). It was published in 2016, in Biomed Res Int.

   Ac-SDKP has no FDA-approved product: Drugs@FDA lists no application for it.

   - Animal study in mice · 2016 [Ac-SDKP taken by mouth eased kidney scarring in diabetic mice](https://pepvault.app/research/tb-500-fragment-nitta-2016)

   - [Ac-SDKP: legal and regulatory status](https://pepvault.app/peptides/tb-500-fragment/legal-status)
   - [Ac-SDKP in the library](https://pepvault.app/peptides/tb-500-fragment)
   - [Ac-SDKP dose guide](https://pepvault.app/lab/dosage/tb-500-fragment)

## On kidney disease

### Semaglutide

- [Semaglutide: the full reference](https://pepvault.app/peptides/semaglutide)
- [Semaglutide dose guide](https://pepvault.app/lab/dosage/semaglutide)

### SS-31

- [SS-31: the full reference](https://pepvault.app/peptides/ss-31)
- [SS-31 dose guide](https://pepvault.app/lab/dosage/ss-31)

### Mixing charts

- [Semaglutide 2 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-2mg)
- [Semaglutide 5 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-5mg)
- [Semaglutide 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-10mg)
- [SS-31 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/ss-31-10mg)
- [SS-31 50 mg vial](https://pepvault.app/tools/reconstitution-calculator/ss-31-50mg)
- [Ac-SDKP 5 mg vial](https://pepvault.app/tools/reconstitution-calculator/tb-500-fragment-5mg)

### Studies

- [Semaglutide: 11.85% more weight loss than placebo without diabetes](https://pepvault.app/research/semaglutide-tan-2022)
- [CagriSema: 18.4% weight loss vs 11.9% on semaglutide in REDEFINE 5](https://pepvault.app/research/cagrisema-redefine-5-2026)
- [CagriSema: HbA1c down 2.33% at 40 weeks in REIMAGINE 3](https://pepvault.app/research/cagrisema-reimagine-3-2026)
- [All 31 studies](https://pepvault.app/research#semaglutide)
- [SS-31 (elamipretide) eye drops missed main vision goal in LHON trial](https://pepvault.app/research/ss-31-karanjia-2024)
- [SS-31: no gain in walk distance or fatigue in the MMPOWER-3 trial](https://pepvault.app/research/ss-31-mmpower-3-2023)
- [SS-31: wearable data grouped responders with 100% accuracy](https://pepvault.app/research/ss-31-van-den-eynde-2023)
- [All 14 studies](https://pepvault.app/research#ss-31)

### Compared with

- [Semaglutide vs Tirzepatide](https://pepvault.app/peptides/compare/semaglutide-vs-tirzepatide)
- [Retatrutide vs Semaglutide](https://pepvault.app/peptides/compare/retatrutide-vs-semaglutide)
- [Orforglipron vs Semaglutide](https://pepvault.app/peptides/compare/orforglipron-vs-semaglutide)
- [Cagrilintide vs Semaglutide](https://pepvault.app/peptides/compare/cagrilintide-vs-semaglutide)
- [Liraglutide vs Semaglutide](https://pepvault.app/peptides/compare/liraglutide-vs-semaglutide)
- [Semaglutide vs Dulaglutide](https://pepvault.app/peptides/compare/semaglutide-vs-dulaglutide)

### Tools

- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)
- [How long will my vial last?](https://pepvault.app/tools/how-long-will-my-vial-last)
- [Is my mixed vial still good?](https://pepvault.app/tools/reconstituted-peptide-expiry)
- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)
- [GLP-1 titration planner](https://pepvault.app/tools/glp1-titration-calculator)
- [GLP-1 weight loss by week](https://pepvault.app/tools/glp1-weight-loss-by-week)

### Related conditions

- [Peptides studied for type 2 diabetes](https://pepvault.app/conditions/type-2-diabetes)
- [Peptides studied for heart disease](https://pepvault.app/conditions/heart-disease)
- [Peptides studied for obesity](https://pepvault.app/conditions/obesity)
- [Peptides studied for fatty liver disease (MASH)](https://pepvault.app/conditions/fatty-liver-disease)

### By goal

- [Peptides for injury recovery and healing](https://pepvault.app/peptides/for/injury-recovery)
- [Peptides for weight loss](https://pepvault.app/peptides/for/weight-loss)

## Side by side

For the 3 compounds on this page: studies in people, studies in animals or cells, the size of the largest study in people, and the FDA status from the labels our status pages read (a dash where they hold no record).

| Compound | In people | Animals or cells | Largest in people | FDA |
| --- | --- | --- | --- | --- |
| [Semaglutide](https://pepvault.app/peptides/semaglutide) | 1 | 0 | 3,533 | Approved, a use tied to it |
| [SS-31](https://pepvault.app/peptides/ss-31) | 1 | 0 | — | Approved for other uses |
| [Ac-SDKP](https://pepvault.app/peptides/tb-500-fragment) | 0 | 1 | — | Not approved |

## What the studies did not show

Each study page names its own limits. These are the questions still open, in the study pages’ words.

- [Semaglutide: 24% lower risk of major kidney events in FLOW](https://pepvault.app/research/semaglutide-flow-2024) The trial included only people with type 2 diabetes and chronic kidney disease within set eGFR and urine albumin ranges, tested a single 1.0 mg dose, and was stopped early. It was funded by Novo Nordisk.
- [SS-31: less kidney hypoxia after renal artery stenting in pilot](https://pepvault.app/research/ss-31-saad-2017) This was a very small pilot trial with 6 and 8 patients per group, so the results are early and need confirming in larger trials. Follow-up lasted only 3 months, and the drug was tested only around a single stenting procedure.
- [Ac-SDKP taken by mouth eased kidney scarring in diabetic mice](https://pepvault.app/research/tb-500-fragment-nitta-2016) This was done in mice, so it is not a result in people. The study did not test oral Ac-SDKP in humans with diabetic kidney disease.

This page is a reading of published studies, not medical advice. A diagnosis, and what to do about it, is a conversation with a clinician.

## Related pages

- [Peptides studied for type 2 diabetes 1 study in common](https://pepvault.app/conditions/type-2-diabetes)
- [Peptides studied for heart disease 3 compounds in common](https://pepvault.app/conditions/heart-disease)
- [Peptides studied for obesity 1 compound in common](https://pepvault.app/conditions/obesity)
- [Peptides studied for fatty liver disease (MASH) 1 compound in common](https://pepvault.app/conditions/fatty-liver-disease)

### By goal

- [Peptides for injury recovery and healing](https://pepvault.app/peptides/for/injury-recovery)
- [Peptides for weight loss](https://pepvault.app/peptides/for/weight-loss)

### Trial terms

- [Randomized controlled trial (RCT)](https://pepvault.app/glossary/randomized-controlled-trial)
- [Placebo](https://pepvault.app/glossary/placebo)
- [Phase 1, 2 and 3 trials](https://pepvault.app/glossary/clinical-trial-phases)
- [Meta-analysis](https://pepvault.app/glossary/meta-analysis)
- [In vivo](https://pepvault.app/glossary/in-vivo)

## Questions

### Which peptides have been studied for kidney disease?

Our 3 study pages on kidney disease are filed under 3 compounds, with this many each: Semaglutide 1, SS-31 1 and Ac-SDKP 1. Semaglutide, SS-31 and Ac-SDKP have the most, 1 each.

### Have any been tested in people with kidney disease?

Yes: 2 of the 3 were in people, all of them meta-analyses or randomized trials (Semaglutide and SS-31). The largest enrolled 3,533 people: “Semaglutide: 24% lower risk of major kidney events in FLOW” (2024).

### Is any peptide FDA-approved for kidney disease?

Yes, with a use tied to kidney disease on their FDA labels: Semaglutide as Ozempic. 2 other compounds here with an FDA record have no use tied to it.

### How large were the studies in people on kidney disease?

Of the 2 in people, 1 gives its size on our pages: 1 had 1,000 people or more. The largest, a randomized trial from 2024, enrolled 3,533.

### What did the animal and cell studies on kidney disease use?

1 animal study (mice), filed under Ac-SDKP. A result in animals or cells shows what to test next, not what happens in a person.

### What is the newest study on kidney disease here?

Of our study pages on kidney disease, the newest is “Semaglutide: 24% lower risk of major kidney events in FLOW”, a randomized trial in people published in 2024.

## How this page was built

A study page is listed here only where we read its question, design and finding and the study was about this condition: its subjects had the condition, or were an animal or cell model of it, and the study gave them the compound. A study that only mentions the condition is not listed.

Studies are grouped by the compound each is filed under and ordered by design: meta-analyses and randomized trials in people first, then other studies in people, then animals, then cells, and within a group by size and then by year. The FDA status comes from the labels our legal-status and brand pages read.

<!--promo-->

[Track it in the app](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=conditions-card-next&mt=8)

<!--/promo-->

<!--promo-->

PepVault for iPhone

## Track your own progress in PepVault

Doses, vials, weight and side effects in one log.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=conditions-card-end&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

<!--promo-->

PepVault for iPhone

## Track your own progress in PepVault

Doses, vials, weight and side effects in one log.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=conditions-card-rail&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## On kidney disease

### Semaglutide

- [Semaglutide: the full reference](https://pepvault.app/peptides/semaglutide)
- [Semaglutide dose guide](https://pepvault.app/lab/dosage/semaglutide)

### SS-31

- [SS-31: the full reference](https://pepvault.app/peptides/ss-31)
- [SS-31 dose guide](https://pepvault.app/lab/dosage/ss-31)

### Mixing charts

- [Semaglutide 2 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-2mg)
- [Semaglutide 5 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-5mg)
- [Semaglutide 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-10mg)
- [SS-31 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/ss-31-10mg)
- [SS-31 50 mg vial](https://pepvault.app/tools/reconstitution-calculator/ss-31-50mg)
- [Ac-SDKP 5 mg vial](https://pepvault.app/tools/reconstitution-calculator/tb-500-fragment-5mg)

### Studies

- [Semaglutide: 11.85% more weight loss than placebo without diabetes](https://pepvault.app/research/semaglutide-tan-2022)
- [CagriSema: 18.4% weight loss vs 11.9% on semaglutide in REDEFINE 5](https://pepvault.app/research/cagrisema-redefine-5-2026)
- [CagriSema: HbA1c down 2.33% at 40 weeks in REIMAGINE 3](https://pepvault.app/research/cagrisema-reimagine-3-2026)
- [All 31 studies](https://pepvault.app/research#semaglutide)
- [SS-31 (elamipretide) eye drops missed main vision goal in LHON trial](https://pepvault.app/research/ss-31-karanjia-2024)
- [SS-31: no gain in walk distance or fatigue in the MMPOWER-3 trial](https://pepvault.app/research/ss-31-mmpower-3-2023)
- [SS-31: wearable data grouped responders with 100% accuracy](https://pepvault.app/research/ss-31-van-den-eynde-2023)
- [All 14 studies](https://pepvault.app/research#ss-31)

### Compared with

- [Semaglutide vs Tirzepatide](https://pepvault.app/peptides/compare/semaglutide-vs-tirzepatide)
- [Retatrutide vs Semaglutide](https://pepvault.app/peptides/compare/retatrutide-vs-semaglutide)
- [Orforglipron vs Semaglutide](https://pepvault.app/peptides/compare/orforglipron-vs-semaglutide)
- [Cagrilintide vs Semaglutide](https://pepvault.app/peptides/compare/cagrilintide-vs-semaglutide)
- [Liraglutide vs Semaglutide](https://pepvault.app/peptides/compare/liraglutide-vs-semaglutide)
- [Semaglutide vs Dulaglutide](https://pepvault.app/peptides/compare/semaglutide-vs-dulaglutide)

### Tools

- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)
- [How long will my vial last?](https://pepvault.app/tools/how-long-will-my-vial-last)
- [Is my mixed vial still good?](https://pepvault.app/tools/reconstituted-peptide-expiry)
- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)
- [GLP-1 titration planner](https://pepvault.app/tools/glp1-titration-calculator)
- [GLP-1 weight loss by week](https://pepvault.app/tools/glp1-weight-loss-by-week)

### Related conditions

- [Peptides studied for type 2 diabetes](https://pepvault.app/conditions/type-2-diabetes)
- [Peptides studied for heart disease](https://pepvault.app/conditions/heart-disease)
- [Peptides studied for obesity](https://pepvault.app/conditions/obesity)
- [Peptides studied for fatty liver disease (MASH)](https://pepvault.app/conditions/fatty-liver-disease)

### By goal

- [Peptides for injury recovery and healing](https://pepvault.app/peptides/for/injury-recovery)
- [Peptides for weight loss](https://pepvault.app/peptides/for/weight-loss)

<!--promo-->

PepVault for iPhone

## Track your own progress in PepVault

Doses, vials, weight and side effects in one log.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=conditions-card-sticky&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

## By condition

- [Every condition](https://pepvault.app/conditions)
- [Peptides studied for type 2 diabetes](https://pepvault.app/conditions/type-2-diabetes)
- [Peptides studied for heart disease](https://pepvault.app/conditions/heart-disease)
- [Peptides studied for obesity](https://pepvault.app/conditions/obesity)
- [Peptides studied for fatty liver disease (MASH)](https://pepvault.app/conditions/fatty-liver-disease)

## The research

- [Studies, in plain English](https://pepvault.app/research)
- [The peptide reference library](https://pepvault.app/peptides)
- [Peptides by goal](https://pepvault.app/peptides/for)

PepVault is a research and tracking resource, not medical advice. Ranges are what studies used, never a dose for you. Brand names are trademarks of their owners; PepVault is independent of them.

PepVault is a private research and tracking tool, not medical advice. The information here is reference material from published literature and community use — always verify it and discuss any protocol with a qualified clinician before changing it.

© 2026 PepVault. Our text, data and tools may not be copied, scraped or republished without [permission](https://pepvault.app/terms#content).
